Vendor, Long Island City, NY
Renbio, Inc.
UEI NMYHCDQN7DR3, CAGE 7K9J1
1 award and $749,289 obligated between April 29, 2024 and May 22, 2025, 100% under full and open competition, against 1.0 offers on average where reported.
Sells to
Awarding agencies by dollars.
| Office of Assistant Secretary for Preparedness and Response | $749,289 |
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $749,289 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75A50124C00017Definitive Contract, April 29, 2024, Full and Open Competition, 1 offers | Barda - Aspr / Daappo / Barda DCMAOffice of Assistant Secretary for Preparedness and Response | Renbio INC. - Aoi#25(Fastx) R&D for Myo Technology for DNA-BASED Delivery of Anti-Influenza Antibodies to Large AnimalsNAICS 541714, PSC AN13 | $749,289 |
- Places of performance
- New York
- Product and service codes
- AN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 4 across 1 awards